Abstract
Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Current Cancer Therapy Reviews
Title: Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Volume: 2 Issue: 1
Author(s): Zakir Khan, Pratiksha Bhadouria, Radha Gupta and Prakash S. Bisen
Affiliation:
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Abstract: Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Export Options
About this article
Cite this article as:
Khan Zakir, Bhadouria Pratiksha, Gupta Radha and Bisen S. Prakash, Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene, Current Cancer Therapy Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339406777592113
DOI https://dx.doi.org/10.2174/157339406777592113 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Impaired Expression and Function of Signaling Pathway Enzymes by Anthocyanins: Role on Cancer Prevention and Progression
Current Enzyme Inhibition The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Diagnosis and Clinical Aspects of Lung Cancer: A Special Emphasis on Drug Targeting to Cancer Cells through Nanoparticles
Letters in Drug Design & Discovery Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry What they are, How they Work and Why they do What they do? The Story of SV40-derived Gene Therapy Vectors and What They Have to Offer
Current Gene Therapy Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry